# An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma

> **NCT01902862** · PHASE2 · TERMINATED · sponsor: **Janssen-Cilag G.m.b.H** · enrollment: 7 (actual)

## Conditions studied

- Lymphoma, Follicular

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01902862
- **Lead sponsor:** Janssen-Cilag G.m.b.H
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-02
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Recruitment too slow
- **Last updated:** 2014-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01902862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01902862, "An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01902862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*